Morgan Stanley on Wednesday adjusted its valuations for two European employee-benefits and payments platforms, increasing its target price for Edenred SA and lowering the target for Pluxee N.V., while leaving both stocks' ratings unchanged.
The broker lifted its price objective on Edenred to €34 from €33, which it says represents roughly 38% upside to the stock. For Pluxee, Morgan Stanley reduced its target to €15.50 from €21.00, which equates to about 18% upside. Despite the divergent price-target moves, the firm maintained an "overweight" rating on Edenred and an "equal-weight" rating on Pluxee, designating Edenred as its preferred play within the subsector.
Valuation and regulatory framing
Morgan Stanley argued that the market currently treats the subsector as one undergoing a rebasing process rather than as structurally impaired businesses, describing the group as a "rebased, cash-generative subsector where Edenred offers the cleaner recovery." The analysts cautioned that regulatory risk appears to be largely priced into both names.
The bank illustrated this point by valuing the businesses with no assigned worth for their Meal & Food divisions. Under that hypothetical, the remainder of the businesses would trade at about 8 times EV/EBIT for Pluxee and 13 times EV/EBIT for Edenred, suggesting the market is already discounting severe regulatory outcomes for both companies.
Growth levers and sensitivity to rates
Morgan Stanley said the market may be underestimating continued growth in the Benefits & Engagement segment. The analysts highlighted several offsetting levers they believe could support growth: SME underpenetration of less than 10%, face-value increases of more than 25% in Italy and Belgium, accelerated cross-selling, and sensitivity to an interest-rate environment that could boost operating profit. Specifically, the bank estimated a 100 basis-point rate increase could lift EBIT by roughly 3% at Edenred and about 6% at Pluxee.
For Edenred, the broker also pointed to a second growth pillar in Mobility, which accounts for approximately one quarter of group EBIT and, according to Morgan Stanley, has delivered about 15% average organic growth over the past decade. The firm said this part of Edenred's business is "completely protected from the regulatory debate."
Near-term growth and valuation view
Morgan Stanley expects Edenred to be capable of mid-single-digit percentage top-line growth even if Meal & Food activity stagnates, versus roughly 3% for Pluxee. The bank described current forward price-to-earnings multiples - roughly 9 times to 11 times next-twelve-month P/E for Pluxee and Edenred - as "too cheap" for companies the analysts forecast will deliver mid-to-high single-digit organic revenue growth and high single-digit EBIT growth. Once regulatory rebasing is behind them, Morgan Stanley projects EPS compound annual growth of 11% to 12% by fiscal 2027.
The analysts also noted that confirmed private equity interest in the sector provides a valuation floor and skews the risk/reward profile to the upside.
Risks highlighted by the broker
Morgan Stanley flagged scenarios that would undermine its view: regulatory developments in France that mirror stricter models seen in Brazil or Italy, or a situation in which the firm is overly optimistic about the identified offsets - for example, if SME penetration remains structurally lower than expected. Such outcomes, the broker warned, could push both stocks lower.